Increased sensitivity of test that detects the second deadliest cancer will save hundreds of lives, oncologists say ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

Multitarget stool DNA tests — which are becoming more popular in the United States — have shown increased sensitivity over fecal immunochemical tests (FITs) for early colorectal cancer (CRC) screening ...

By reducing the level at which traces of blood in a FIT test trigger further investigation – from 120 micrograms of blood per gram of poo down to 80 – the NHS will offer 35% more screening ...

Please provide your email address to receive an email when new articles are posted on . Males, African Americans and people with Medicaid are more likely to submit an unsatisfactory sample. Less than ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Mayo Clinic researchers conducted a study comparing the efficacy of multitarget stool DNA tests to fecal immunochemical testing for colorectal cancer screening in Alaska Native people. Here are six ...

Conclusions In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded ...

Colorectal cancer (CRC) is a leading cause of death among men and women in the USA. Encouragingly, the reported death rates from CRC in the USA have dropped by 46%, and screening has had an important ...